Implications of Cardiopulmonary Risk for the Management of COPD: A Narrative Review.
Cardiopulmonary risk
Cardiovascular disease
Chronic obstructive pulmonary disease
Exacerbation
Inhaled therapy
Mortality
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
25 Apr 2024
25 Apr 2024
Historique:
received:
23
02
2024
accepted:
22
03
2024
medline:
26
4
2024
pubmed:
26
4
2024
entrez:
25
4
2024
Statut:
aheadofprint
Résumé
Chronic obstructive pulmonary disease (COPD) constitutes a major global health burden and is the third leading cause of death worldwide. A high proportion of patients with COPD have cardiovascular disease, but there is also evidence that COPD is a risk factor for adverse outcomes in cardiovascular disease. Patients with COPD frequently die of respiratory and cardiovascular causes, yet the identification and management of cardiopulmonary risk remain suboptimal owing to limited awareness and clinical intervention. Acute exacerbations punctuate the progression of COPD in many patients, reducing lung function and increasing the risk of subsequent exacerbations and cardiovascular events that may lead to early death. This narrative review defines and summarises the principles of COPD-associated cardiopulmonary risk, and examines respiratory interventions currently available to modify this risk, as well as providing expert opinion on future approaches to addressing cardiopulmonary risk.
Identifiants
pubmed: 38664329
doi: 10.1007/s12325-024-02855-4
pii: 10.1007/s12325-024-02855-4
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5: 020415. https://doi.org/10.7189/jogh.05.020415 .
doi: 10.7189/jogh.05.020415
pubmed: 26755942
pmcid: 4693508
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease report 2024. https://goldcopd.org/2024-gold-report/ . Accessed 5 Jan 2024.
World Health Organization. Chronic obstructive pulmonary disease (COPD) 2023. https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd ). Accessed 6 Feb 2024.
Mathers C. Projections of global deaths from 2016 to 2060 2022. https://colinmathers.com/2022/05/10/projections-of-global-deaths-from-2016-to-2060/ . Accessed 9 Nov 2023.
Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3:631–9. https://doi.org/10.1016/S2213-2600(15)00241-6 .
doi: 10.1016/S2213-2600(15)00241-6
pubmed: 26208998
Amegadzie JE, Sadatsafavi M. A long overdue recognition: COPD as a distinct predictor of cardiovascular disease risk. Eur Respir J. 2023;62:2301167. https://doi.org/10.1183/13993003.01167-2023 .
doi: 10.1183/13993003.01167-2023
pubmed: 37652564
Müllerova H, Agusti A, Erqou S, Mapel DW. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144:1163–78. https://doi.org/10.1378/chest.12-2847 .
doi: 10.1378/chest.12-2847
pubmed: 23722528
Forfia PR, Vaidya A, Wiegers SE. Pulmonary heart disease: the heart-lung interaction and its impact on patient phenotypes. Pulm Circ. 2013;3:5–19. https://doi.org/10.4103/2045-8932.109910 .
doi: 10.4103/2045-8932.109910
pubmed: 23662171
pmcid: 3641739
Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med. 2013;1:73–83. https://doi.org/10.1016/S2213-2600(12)70060-7 .
doi: 10.1016/S2213-2600(12)70060-7
pubmed: 24321806
Maclagan LC, Croxford R, Chu A, Sin DD, Udell JA, Lee DS, et al. Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort. Eur Respir J. 2023;62:2202364. https://doi.org/10.1183/13993003.02364-2022 .
doi: 10.1183/13993003.02364-2022
pubmed: 37385658
Fabbri LM, Celli BR, Agustí A, Criner GJ, Dransfield MT, Divo M, et al. COPD and multimorbidity: recognising and addressing a syndemic occurrence. Lancet Respir Med. 2023;11:1020–34. https://doi.org/10.1016/S2213-2600(23)00261-8 .
doi: 10.1016/S2213-2600(23)00261-8
pubmed: 37696283
Hurst JR, Skolnik N, Hansen GJ, Anzueto A, Donaldson GC, Dransfield MT, et al. Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life. Eur J Intern Med. 2020;73:1–6. https://doi.org/10.1016/j.ejim.2019.12.014 .
doi: 10.1016/j.ejim.2019.12.014
pubmed: 31954592
Hughes R, Rapsomaniki E, Janson C, Keen C, Make BJ, Burgel P-R, et al. Frequent productive cough: symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study. Respir Med. 2022;200: 106921. https://doi.org/10.1016/j.rmed.2022.106921 .
doi: 10.1016/j.rmed.2022.106921
pubmed: 35820227
Kunisaki KM, Dransfield MT, Anderson JA, Brook RD, Calverley PM, Celli BR, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med. 2018;198:51–7. https://doi.org/10.1164/rccm.201711-2239OC .
doi: 10.1164/rccm.201711-2239OC
pubmed: 29442524
pmcid: 6913068
Rothnie KJ, Müllerová H, Smeeth L, Quint JK. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198:464–71. https://doi.org/10.1164/rccm.201710-2029OC .
doi: 10.1164/rccm.201710-2029OC
pubmed: 29474094
pmcid: 6118021
Mannino DM, Doherty DE, Sonia BA. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med. 2006;100:115–22. https://doi.org/10.1016/j.rmed.2005.03.035 .
doi: 10.1016/j.rmed.2005.03.035
pubmed: 15893923
Foos V, Mcewan P, Holmgren U, Marshall J, Müllerová H, Nigris ED. Projections of 10-year mortality in patients with COPD in the UK using the CHOPIN policy model. Eur Respir J. 2021;58(Suppl. 65):PA1012. https://doi.org/10.1183/13993003.congress-2021.PA1012 . (Abstract).
doi: 10.1183/13993003.congress-2021.PA1012
Matarese A, Sardu C, Shu J, Santulli G. Why is chronic obstructive pulmonary disease linked to atrial fibrillation? A systematic overview of the underlying mechanisms. Int J Cardiol. 2019;276:149–51. https://doi.org/10.1016/j.ijcard.2018.10.075 .
doi: 10.1016/j.ijcard.2018.10.075
pubmed: 30446289
Chen C-C, Lin C-H, Hao W-R, Chiu C-C, Fang Y-A, Liu J-C, et al. Association between chronic obstructive pulmonary disease and ventricular arrhythmia: a nationwide population-based cohort study. NPJ Prim Care Respir Med. 2021;31:8. https://doi.org/10.1038/s41533-021-00221-3 .
doi: 10.1038/s41533-021-00221-3
pubmed: 33580036
pmcid: 7880986
Liu X, Chen Z, Li S, Xu S. Association of chronic obstructive pulmonary disease with arrhythmia risks: a systematic review and meta-analysis. Front Cardiovasc Med. 2021;8: 732349. https://doi.org/10.3389/fcvm.2021.732349 .
doi: 10.3389/fcvm.2021.732349
pubmed: 34660734
pmcid: 8514787
Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis. 2009;4:337–49. https://doi.org/10.2147/copd.s6400 .
doi: 10.2147/copd.s6400
pubmed: 19802349
pmcid: 2754086
Krishnan S, Tan WC, Farias R, Aaron SD, Benedetti A, Chapman KR, et al. Impaired spirometry and COPD increase the risk of cardiovascular disease: a Canadian cohort study. Chest. 2023;164:637–49. https://doi.org/10.1016/j.chest.2023.02.045 .
doi: 10.1016/j.chest.2023.02.045
pubmed: 36871842
Carter P, Lagan J, Fortune C, Bhatt DL, Vestbo J, Niven R, et al. Association of cardiovascular disease with respiratory disease. J Am Coll Cardiol. 2019;73:2166–77. https://doi.org/10.1016/j.jacc.2018.11.063 .
doi: 10.1016/j.jacc.2018.11.063
pubmed: 30846341
Amegadzie JE, Gao Z, Quint JK, Russell R, Hurst JR, Lee TY, et al. QRISK3 underestimates the risk of cardiovascular events in patients with COPD. Thorax. 2023. https://doi.org/10.1136/thorax-2023-220615 .
doi: 10.1136/thorax-2023-220615
pubmed: 38050168
Watz H, Tetzlaff K, Magnussen H, Mueller A, Rodriguez-Roisin R, Wouters EF, et al. Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial. Respir Res. 2018;19:251. https://doi.org/10.1186/s12931-018-0944-3 .
doi: 10.1186/s12931-018-0944-3
pubmed: 30545350
pmcid: 6293570
Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67:957–63. https://doi.org/10.1136/thoraxjnl-2011-201518 .
doi: 10.1136/thoraxjnl-2011-201518
pubmed: 22684094
Goto T, Shimada YJ, Faridi MK, Camargo CA, Hasegawa K. Incidence of acute cardiovascular event after acute exacerbation of COPD. J Gen Intern Med. 2018;33:1461–8. https://doi.org/10.1007/s11606-018-4518-3 .
doi: 10.1007/s11606-018-4518-3
pubmed: 29948806
pmcid: 6108996
Müllerová H, Marshall J, de Nigris E, Varghese P, Pooley N, Embleton N, et al. Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis. Ther Adv Respir Dis. 2022;16:17534666221113648. https://doi.org/10.1177/17534666221113647 .
doi: 10.1177/17534666221113647
pubmed: 35894441
pmcid: 9340406
Nordon C, Rhodes K, Quint JK, Vogelmeier CF, Simons SO, Hawkins NM, et al. EXAcerbations of COPD and their OutcomeS on CardioVascular diseases (EXACOS-CV) Programme: protocol of multicountry observational cohort studies. BMJ Open. 2023;13: e070022. https://doi.org/10.1136/bmjopen-2022-070022 .
doi: 10.1136/bmjopen-2022-070022
pubmed: 37185641
pmcid: 10151875
Graul EL, Nordon C, Rhodes K, Marshall J, Menon S, Kallis C, et al. Temporal risk of non-fatal cardiovascular events post COPD exacerbation: a population-based study. Am J Respir Crit Care Med. 2023. https://doi.org/10.1164/rccm.202307-1122OC .
doi: 10.1164/rccm.202307-1122OC
Hawkins NM, Nordon C, Rhodes K, Talukdar M, McMullen S, Ekwaru P, et al. Heightened long-term cardiovascular risks after exacerbation of chronic obstructive pulmonary disease. Heart. 2024. https://doi.org/10.1136/heartjnl-2023-323487 .
doi: 10.1136/heartjnl-2023-323487
pubmed: 38182279
Vogelmeier C, Simons S, Garbe E, Sin D, Hawkins N, Manito N, et al. Increased risk of severe cardiovascular events following exacerbations of COPD: a multi-database cohort study. Eur Respir J 2023;62:PA3013 (Abstract).
Swart KMA, Baak BN, Lemmens L, Penning-van Beest FJA, Bengtsson C, Lobier M, et al. Risk of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: results from the EXACOS-CV cohort study using the PHARMO Data Network in the Netherlands. Respir Res. 2023;24:293. https://doi.org/10.1186/s12931-023-02601-4 .
doi: 10.1186/s12931-023-02601-4
pubmed: 37990197
pmcid: 10662240
Dransfield MT, Criner GJ, Halpin, Han MK, Hartley B, Kalhan R, et al. Time‐dependent risk of cardiovascular events following an exacerbation in patients with chronic obstructive pulmonary disease: post hoc analysis from the IMPACT trial. J Am Heart Assoc 2022;11:e024350. https://doi.org/10.1161/JAHA.121.024350 .
Westerik JA, Metting EI, van Boven JF, Tiersma W, Kocks JW, Schermer TR. Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. Respir Res. 2017;18:31. https://doi.org/10.1186/s12931-017-0512-2 .
doi: 10.1186/s12931-017-0512-2
pubmed: 28166777
pmcid: 5294875
Curkendall SM, deLuise C, Jones JK, Lanes S, Stang MR, Goehring E, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada: cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16:63–70. https://doi.org/10.1016/j.annepidem.2005.04.008 .
doi: 10.1016/j.annepidem.2005.04.008
pubmed: 16039877
Williams MC, Murchison JT, Edwards LD, Agustí A, Bakke P, Calverley PM, et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax. 2014;69:718–23. https://doi.org/10.1136/thoraxjnl-2012-203151 .
doi: 10.1136/thoraxjnl-2012-203151
pubmed: 24473329
Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–38. https://doi.org/10.1056/NEJMoa0909883 .
doi: 10.1056/NEJMoa0909883
pubmed: 20843247
Sadatsafavi M, McCormack J, Petkau J, Lynd LD, Lee TY, Sin DD. Should the number of acute exacerbations in the previous year be used to guide treatments in COPD? Eur Respir J. 2021;57:2002122. https://doi.org/10.1183/13993003.02122-2020 .
doi: 10.1183/13993003.02122-2020
pubmed: 32855228
pmcid: 7876420
Ho JK, Safari A, Adibi A, Sin DD, Johnson K, Sadatsafavi M, et al. Generalizability of risk stratification algorithms for exacerbations in COPD. Chest. 2023;163:790–8. https://doi.org/10.1016/j.chest.2022.11.041 .
doi: 10.1016/j.chest.2022.11.041
pubmed: 36509123
Sharma V, Ali I, van der Veer S, Martin G, Ainsworth J, Augustine T. Adoption of clinical risk prediction tools is limited by a lack of integration with electronic health records. BMJ Health Care Inform. 2021;28: e100253. https://doi.org/10.1136/bmjhci-2020-100253 .
doi: 10.1136/bmjhci-2020-100253
pubmed: 33608259
pmcid: 7898839
Dudina A, Lane S, Butler M, Cooney M-T, Graham I. SURF-COPD: the recording of cardiovascular risk in patients with chronic lung disease. QJM. 2018;111:303–6. https://doi.org/10.1093/qjmed/hcy028 .
doi: 10.1093/qjmed/hcy028
pubmed: 29432601
Müllerová H, Shukla A, Hawkins A, Quint J. Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open. 2014;4: e006171. https://doi.org/10.1136/bmjopen-2014-006171 .
doi: 10.1136/bmjopen-2014-006171
pubmed: 25524545
pmcid: 4275672
Rapsomaniki E, Müllerová H, Hughes R, Marshall J, Papi A, Reddel H, et al. Frequent productive cough associates with an increased risk of cardiopulmonary outcomes in a real-life cohort of patients with COPD (NOVELTY study). Eur Respir J. 2023;62(Suppl. 67):PA1928 (Abstract).
Van Eeden S, Leipsic J, Paul Man SF, Sin DD. The relationship between lung inflammation and cardiovascular disease. Am J Respir Crit Care Med. 2012;186:11–6. https://doi.org/10.1164/rccm.201203-0455PP .
doi: 10.1164/rccm.201203-0455PP
pubmed: 22538803
Aisanov Z, Khaltaev N. Management of cardiovascular comorbidities in chronic obstructive pulmonary disease patients. J Thorac Dis. 2020;12:2791–802. https://doi.org/10.21037/jtd.2020.03.60 .
doi: 10.21037/jtd.2020.03.60
pubmed: 32642187
pmcid: 7330365
Vassaux C, Torre-Bouscoulet L, Zeineldine S, Cortopassi F, Paz-Díaz H, Celli BR, et al. Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD. Eur Respir J. 2008;32:1275–82. https://doi.org/10.1183/09031936.00151707 .
doi: 10.1183/09031936.00151707
pubmed: 18550609
Kent BD, Mitchell PD, McNicholas WT. Hypoxemia in patients with COPD: cause, effects, and disease progression. Int J Chron Obstruct Pulmon Dis. 2011;6:199–208. https://doi.org/10.2147/COPD.S10611 .
doi: 10.2147/COPD.S10611
pubmed: 21660297
pmcid: 3107696
Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev. 2018;27: 180057. https://doi.org/10.1183/16000617.0057-2018 .
doi: 10.1183/16000617.0057-2018
pubmed: 30282634
pmcid: 9488649
Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–54. https://doi.org/10.1056/NEJMoa0805800 .
doi: 10.1056/NEJMoa0805800
pubmed: 18836213
Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364:1093–103. https://doi.org/10.1056/NEJMoa1008378 .
doi: 10.1056/NEJMoa1008378
pubmed: 21428765
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD. N Engl J Med. 2016;374:2222–34. https://doi.org/10.1056/NEJMoa1516385 .
doi: 10.1056/NEJMoa1516385
pubmed: 27181606
Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671–80. https://doi.org/10.1056/NEJMoa1713901 .
doi: 10.1056/NEJMoa1713901
pubmed: 29668352
Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383:35–48. https://doi.org/10.1056/NEJMoa1916046 .
doi: 10.1056/NEJMoa1916046
pubmed: 32579807
Halpin DM, Dransfield MT, Han MK, Jones CE, Kilbride S, Lange P, et al. The effect of exacerbation history on outcomes in the IMPACT trial. Eur Respir J. 2020;55:1901921. https://doi.org/10.1183/13993003.01921-2019 .
doi: 10.1183/13993003.01921-2019
pubmed: 32299860
pmcid: 7286387
Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196:438–46. https://doi.org/10.1164/rccm.201703-0449OC .
doi: 10.1164/rccm.201703-0449OC
pubmed: 28375647
Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6:747–58. https://doi.org/10.1016/S2213-2600(18)30327-8 .
doi: 10.1016/S2213-2600(18)30327-8
pubmed: 30232048
Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389:1919–29. https://doi.org/10.1016/S0140-6736(17)30188-5 .
doi: 10.1016/S0140-6736(17)30188-5
pubmed: 28385353
Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β
doi: 10.1016/S0140-6736(16)31354-X
pubmed: 27598678
Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391:1076–84. https://doi.org/10.1016/S0140-6736(18)30206-X .
doi: 10.1016/S0140-6736(18)30206-X
pubmed: 29429593
Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post hoc analysis of three randomised trials. Lancet Respir Med. 2018;6:117–26. https://doi.org/10.1016/S2213-2600(18)30006-7 .
doi: 10.1016/S2213-2600(18)30006-7
pubmed: 29331313
Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7:745–56. https://doi.org/10.1016/S2213-2600(19)30190-0 .
doi: 10.1016/S2213-2600(19)30190-0
pubmed: 31281061
Bafadhel M, Rabe KF, Martinez FJ, Singh D, Darken P, Jenkins M, et al. Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on COPD exacerbations, lung function, symptoms, and quality of life across blood eosinophil ranges: a post hoc analysis of data from ETHOS. Int J Chron Obstruct Pulmon Dis. 2022;17:3061–73. https://doi.org/10.2147/COPD.S374670 .
doi: 10.2147/COPD.S374670
pubmed: 36510486
pmcid: 9738173
Strange C, Tkacz J, Schinkel J, Lewing B, Agatep B, Swisher S, et al. Int J Chron Obstruct Pulmon Dis. 2023;18:2245–2256. https://doi.org/10.2147/COPD.S432963
doi: 10.2147/COPD.S432963
pubmed: 37849918
pmcid: 10577086
Ismaila AS, Rothnie KJ, Wood RP, Banks VL, Camidge LJ, Czira A, et al. Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study. Respir Res. 2023;24:229. https://doi.org/10.1186/s12931-023-02523-1 .
doi: 10.1186/s12931-023-02523-1
pubmed: 37749551
pmcid: 10521462
Löfdahl C-G, Postma DS, Pride NB, Boe J, Thorén A. Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur Respir J. 2007;29:1115–9. https://doi.org/10.1183/09031936.00128806 .
doi: 10.1183/09031936.00128806
pubmed: 17331963
Hohlfeld JM, Vogel-Claussen J, Biller H, Berliner D, Berschneider K, Tillmann H-C, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018;6:368–78. https://doi.org/10.1016/S2213-2600(18)30054-7 .
doi: 10.1016/S2213-2600(18)30054-7
pubmed: 29477448
Kellerer C, Kahnert K, Trudzinski FC, Lutter J, Berschneider K, Speicher T, et al. COPD maintenance medication is linked to left atrial size: results from the COSYCONET cohort. Respir Med. 2021;185: 106461. https://doi.org/10.1016/j.rmed.2021.106461 .
doi: 10.1016/j.rmed.2021.106461
pubmed: 34116329
Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387:1817–26. https://doi.org/10.1016/S0140-6736(16)30069-1 .
doi: 10.1016/S0140-6736(16)30069-1
pubmed: 27203508
Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Singh D, Wang C, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for COPD: a randomized, double-blind, multi-center, parallel-group study. Am J Respir Crit Care Med. 2020;203:553–64. https://doi.org/10.1164/rccm.202006-2618OC .
doi: 10.1164/rccm.202006-2618OC
Lipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DM, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in COPD patients. Am J Respir Crit Care Med. 2020;201:1508–16. https://doi.org/10.1164/rccm.201911-2207OC .
doi: 10.1164/rccm.201911-2207OC
pubmed: 32162970
pmcid: 7301738
Vestbo J, Fabbri L, Papi A, Petruzzelli S, Scuri M, Guasconi A, et al. Inhaled corticosteroid containing combinations and mortality in COPD. Eur Respir J. 2018;52:1801230. https://doi.org/10.1183/13993003.01230-2018 .
doi: 10.1183/13993003.01230-2018
pubmed: 30209195
Yang M, Li Y, Jiang Y, Guo S, He J-Q, Sin DD. Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis. Eur Respir J. 2023;61:2200302. https://doi.org/10.1183/13993003.00302-2022 .
doi: 10.1183/13993003.00302-2022
pubmed: 36137586
Regard L, Burgel P-R, Roche N. Inhaled therapy, cardiovascular risk and benefit–risk considerations in COPD: innocent until proven guilty, or vice versa? Eur Respir J. 2023;61:2202135. https://doi.org/10.1183/13993003.02135-2022 .
doi: 10.1183/13993003.02135-2022
pubmed: 36758999
Stolz D, Cazzola M. Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists. In: Martínez-García MÁ, Pépin J-L, Cazzola M, editors. Cardiovascular complications of respiratory disorders. Sheffield: European Respiratory Society; 2020. p. 238–50. https://doi.org/10.1183/2312508X.10028619 .
doi: 10.1183/2312508X.10028619
Godtfredsen NS, Lam TH, Hansel TT, Leon ME, Gray N, Dresler C, et al. COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur Respir J. 2008;32:844–53. https://doi.org/10.1183/09031936.00160007 .
doi: 10.1183/09031936.00160007
pubmed: 18827152
Ryrsø CK, Godtfredsen NS, Kofod LM, Lavesen M, Mogensen L, Tobberup R, et al. Lower mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a systematic review and meta-analysis. BMC Pulm Med. 2018;18:154. https://doi.org/10.1186/s12890-018-0718-1 .
doi: 10.1186/s12890-018-0718-1
pubmed: 30219047
pmcid: 6139159
Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med. 1980;93:391–8. https://doi.org/10.7326/0003-4819-93-3-391 .
doi: 10.7326/0003-4819-93-3-391
Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet. 1981;317:681–6. https://doi.org/10.1016/S0140-6736(81)91970-X .
doi: 10.1016/S0140-6736(81)91970-X
Murphy PB, Rehal S, Arbane G, Bourke S, Calverley PM, Crook AM, et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. JAMA. 2017;317:2177–86. https://doi.org/10.1001/jama.2017.4451 .
doi: 10.1001/jama.2017.4451
pubmed: 28528348
pmcid: 5710342
Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–89.
doi: 10.1056/NEJMoa063070
pubmed: 17314337
Pullen R, Miravitlles M, Sharma A, Singh D, Martinez F, Hurst JR, et al. CONQUEST quality standards: for the collaboration on quality improvement initiative for achieving excellence in standards of COPD care. Int J Chron Obstruct Pulmon Dis. 2021;16:2301–22. https://doi.org/10.2147/COPD.S313498 .
doi: 10.2147/COPD.S313498
pubmed: 34413639
pmcid: 8370848
Celi A, Latorre M, Paggiaro P, Pistelli R. Chronic obstructive pulmonary disease: moving from symptom relief to mortality reduction. Ther Adv Chronic Dis. 2021;12:20406223211014028. https://doi.org/10.1177/20406223211014028 .
doi: 10.1177/20406223211014028
pmcid: 8127735
O’Donnell DE, Webb KA, Neder JA. Lung hyperinflation in COPD: applying physiology to clinical practice. COPD Res Pract. 2015;1:4. https://doi.org/10.1186/s40749-015-0008-8 .
doi: 10.1186/s40749-015-0008-8
García-Río F. Lung hyperinflation in chronic obstructive pulmonary disease: clinical and therapeutic relevance. BRN Rev. 2020;6:67–86.
Hwang HJ, Lee SM, Seo JB, Lee JS, Kim N, Kim C, et al. Assessment of changes in regional xenon-ventilation, perfusion, and ventilation-perfusion mismatch using dual-energy computed tomography after pharmacological treatment in patients with chronic obstructive pulmonary disease: visual and quantitative analysis. Int J Chron Obstruct Pulmon Dis. 2019;14:2195–203. https://doi.org/10.2147/COPD.S210555 .
doi: 10.2147/COPD.S210555
pubmed: 31576116
pmcid: 6768130
Singh D, Wild JM, Saralaya D, Lawson R, Marshall H, Goldin J, et al. Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial. Respir Res. 2022;23:26. https://doi.org/10.1186/s12931-022-01949-3 .
doi: 10.1186/s12931-022-01949-3
pubmed: 35144620
pmcid: 8832861
Voskrebenzev A, Kaireit TF, Klimeš F, Pöhler GH, Behrendt L, Biller H, et al. PREFUL MRI depicts dual bronchodilator changes in COPD: a retrospective analysis of a randomized controlled trial. Radiol Cardiothorac Imaging. 2022;4: e210147. https://doi.org/10.1148/ryct.210147 .
doi: 10.1148/ryct.210147
pubmed: 35506142
pmcid: 9059092
Shrikrishna D, Taylor CJ, Stonham C, Gale CP. Exacerbating the burden of cardiovascular disease: how can we address cardiopulmonary risk in individuals with chronic obstructive pulmonary disease? Eur Heart J. 2024;45:247–9. https://doi.org/10.1093/eurheartj/ehad669 .
doi: 10.1093/eurheartj/ehad669
pubmed: 37832033
Singh D, Holmes S, Adams C, Bafadhel M, Hurst JR. Overcoming therapeutic inertia to reduce the risk of COPD exacerbations: four action points for healthcare professionals. Int J Chron Obstruct Pulmon Dis. 2021;16:3009–16. https://doi.org/10.2147/COPD.S329316 .
doi: 10.2147/COPD.S329316
pubmed: 34754186
pmcid: 8570921
Kocks J, Ferreira AJ, Bakke P, van Schayck OC, Ekroos H, Tzanakis N, et al. Investigating the rationale for COPD maintenance therapy prescription across Europe, findings from a multi-country study. NPJ Prim Care Respir Med. 2023;33:18. https://doi.org/10.1038/s41533-023-00334-x .
doi: 10.1038/s41533-023-00334-x
pubmed: 37137900
pmcid: 10154184
Mannino D, Siddall J, Small M, Haq A, Stiegler M, Bogart M. Treatment patterns for chronic obstructive pulmonary disease (COPD) in the United States: results from an observational cross-sectional physician and patient survey. Int J Chron Obstruct Pulmon Dis. 2022;17:749–61. https://doi.org/10.2147/COPD.S340794 .
doi: 10.2147/COPD.S340794
pubmed: 35418752
pmcid: 8995154
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease report 2023. https://goldcopd.org/wp-content/uploads/2023/03/GOLD-2023-ver-1.3-17Feb2023_WMV.pdf . Accessed 18 Jan 2024.
Bourbeau J, Bhutani M, Hernandez P, Aaron SD, Beauchesne M-F, Kermelly SB, et al. 2023 Canadian Thoracic Society guideline on pharmacotherapy in patients with stable COPD. Chest. 2023;164:1159–83. https://doi.org/10.1016/j.chest.2023.08.014 .
doi: 10.1016/j.chest.2023.08.014
pubmed: 37690008
Agusti A, Böhm M, Celli B, Criner GJ, Garcia-Alvarez A, Martinez F, et al. GOLD COPD DOCUMENT 2023: a brief update for practicing cardiologists. Clin Res Cardiol. 2023;2023:1–10. https://doi.org/10.1007/s00392-023-02217-0 .
doi: 10.1007/s00392-023-02217-0